Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Obesity

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 94 articles:
HTML format



Single Articles


    November 2024
  1. PACKER M, Zile MR, Kramer CM, Baum SJ, et al
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027.
    PubMed     Abstract available


  2. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414470.
    PubMed    


  3. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available


    October 2024
  4. BLIDDAL H, Bays H, Czernichow S, Udden Hemmingsson J, et al
    Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
    N Engl J Med. 2024;391:1573-1583.
    PubMed     Abstract available



  5. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024;391:1464.
    PubMed    


    September 2024
  6. DRUCKER DJ
    Discovery of GLP-1-Based Drugs for the Treatment of Obesity.
    N Engl J Med. 2024 Sep 19. doi: 10.1056/NEJMcibr2409089.
    PubMed    


  7. BARRETT T, Hamilton-Shield J
    Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMe2410560.
    PubMed    


  8. FOX CK, Barrientos-Perez M, Bomberg EM, Dcruz J, et al
    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2407379.
    PubMed     Abstract available


    July 2024
  9. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    


  10. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    


  11. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    


  12. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    


    June 2024
  13. MALHOTRA A, Grunstein RR, Fietze I, Weaver TE, et al
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024 Jun 21. doi: 10.1056/NEJMoa2404881.
    PubMed     Abstract available



  14. Treating Obesity in Kids: ITT Episode 31.
    N Engl J Med. 2024;390:e52.
    PubMed    


    May 2024
  15. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    


  16. EGAN JM
    Physiological Integration of Taste and Metabolism.
    N Engl J Med. 2024;390:1699-1710.
    PubMed    


    April 2024
  17. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available


    February 2024
  18. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    


  19. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    


  20. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  21. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  22. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    


  23. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    


  24. GORTMAKER SL, Bleich SN, Williams DR
    Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
    N Engl J Med. 2024;390:681-683.
    PubMed    


  25. GOLOVATY I, Hagan S
    Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
    N Engl J Med. 2024;390:677-680.
    PubMed    


    December 2023
  26. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    


  27. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    


  28. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    


  29. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    


  30. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    


  31. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    


  32. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    


    November 2023
  33. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available


  34. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    


    October 2023
  35. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    


  36. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    


  37. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    


  38. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    


  39. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    


  40. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    


    August 2023

  41. Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    


  42. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available


  43. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    


    July 2023
  44. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    


    June 2023
  45. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available


  46. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available


  47. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    


  48. ROSEN CJ
    Antagonizing the Leptin Receptor in Obesity.
    N Engl J Med. 2023;388:2291-2293.
    PubMed    


  49. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
    Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
    N Engl J Med. 2023;388:2253-2261.
    PubMed     Abstract available


    March 2023
  50. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    


  51. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    


  52. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    


    November 2022
  53. WEGHUBER D, Barrett T, Barrientos-Perez M, Gies I, et al
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2208601.
    PubMed     Abstract available


    October 2022
  54. JASTREBOFF AM, Aronne LJ, Stefanski A
    Tirzepatide Once Weekly for the Treatment of Obesity. Reply.
    N Engl J Med. 2022;387:1434-1435.
    PubMed    


  55. VENNIYOOR A
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433-1434.
    PubMed    


  56. HAGERICH K, Durkee M, Goldstein MG
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433.
    PubMed    


  57. DEKKER TJA
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022;387:1433.
    PubMed    


  58. CREANGA AA, Catalano PM, Bateman BT
    Obesity in Pregnancy. Reply.
    N Engl J Med. 2022;387:1339.
    PubMed    


  59. HENDERSON JL, Eke AC
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:1338-1339.
    PubMed    


  60. ZHOU H, Liu X, Li W
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:1338.
    PubMed    


    September 2022
  61. KUHNEN P, Clement K
    Long-Term MC4R Agonist Treatment in POMC-Deficient Patients.
    N Engl J Med. 2022;387:852-854.
    PubMed    


    August 2022
  62. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
    Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    N Engl J Med. 2022;387:599-610.
    PubMed     Abstract available


    July 2022
  63. DE OLIVEIRA EM, Keogh JM, Farooqi IS
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway. Reply.
    N Engl J Med. 2022;387:285-286.
    PubMed    


  64. KLEINENDORST L, Boon E, van Haelst MM
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:285.
    PubMed    


  65. OKUBO J, Mancini MC, de Melo ME
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:284.
    PubMed    


  66. POON KS, Tan KM
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2022;387:284.
    PubMed    


  67. CREANGA AA, Catalano PM, Bateman BT
    Obesity in Pregnancy.
    N Engl J Med. 2022;387:248-259.
    PubMed    


    June 2022
  68. JASTREBOFF AM, Aronne LJ, Ahmad NN, Wharton S, et al
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2206038.
    PubMed     Abstract available


  69. ROSEN CJ, Ingelfinger JR
    Shifting Tides Offer New Hope For Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMe2206939.
    PubMed    


    April 2022
  70. LIU D, Huang Y, Huang C, Yang S, et al
    Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
    N Engl J Med. 2022;386:1495-1504.
    PubMed     Abstract available


    February 2022
  71. CYPESS AM
    Reassessing Human Adipose Tissue.
    N Engl J Med. 2022;386:768-779.
    PubMed    


    December 2021
  72. HAGAN S
    E66.01 and Our Culture of Shame.
    N Engl J Med. 2021;385:2307-2309.
    PubMed    


    October 2021
  73. JUPPNER H
    Obesity and Galphas Variants.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMe2113123.
    PubMed    


  74. MENDES DE OLIVEIRA E, Keogh JM, Talbot F, Henning E, et al
    Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2103329.
    PubMed     Abstract available


    August 2021
  75. JENSEN SBK, Torekov SS
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Reply.
    N Engl J Med. 2021;385:573-574.
    PubMed    


  76. OKECHUKWU CE
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;385:572-573.
    PubMed    


  77. DE SOUTO BARRETO P, Rolland Y
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;385:572.
    PubMed    


    July 2021
  78. ROSEN CJ, Ingelfinger JR
    Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2021;385:e4.
    PubMed    


  79. WILDING JPH, Calanna S, Kushner RF
    Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2021;385:e4.
    PubMed    


  80. SRIVASTAVA G, Kumar RB
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    


  81. NADOLSKY KZ, Agarwal M
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    


  82. KHOO TK, Lin J
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    


  83. JAVOR E, Lucijanic M, Skelin M
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021;385:e4.
    PubMed    


    June 2021
  84. WU JM
    Stress Incontinence in Women.
    N Engl J Med. 2021;384:2428-2436.
    PubMed    


    May 2021
  85. LUNDGREN JR, Janus C, Jensen SBK, Juhl CR, et al
    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    N Engl J Med. 2021;384:1719-1730.
    PubMed     Abstract available


    March 2021
  86. RATHMELL JC
    Obesity, Immunity, and Cancer.
    N Engl J Med. 2021;384:1160-1162.
    PubMed    


  87. INGELFINGER JR, Rosen CJ
    STEP 1 for Effective Weight Control - Another First Step?
    N Engl J Med. 2021;384:1066-1067.
    PubMed    


    February 2021
  88. WILDING JPH, Batterham RL, Calanna S, Davies M, et al
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021 Feb 10. doi: 10.1056/NEJMoa2032183.
    PubMed     Abstract available


    January 2021
  89. CARLSSON LMS, Jacobson P, Peltonen M
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study. Reply.
    N Engl J Med. 2021;384:89.
    PubMed    


  90. GILLION V, Demoulin N, Devresse A
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study.
    N Engl J Med. 2021;384:88.
    PubMed    


  91. TAGLIABUE E, Ceriani V, Pontiroli AE
    Life Expectancy after Bariatric Surgery - the Swedish Obese Subjects Study.
    N Engl J Med. 2021;384:88.
    PubMed    


    December 2020
  92. KUMANYIKA S, Dietz WH
    Solving Population-wide Obesity - Progress and Future Prospects.
    N Engl J Med. 2020;383:2197-2200.
    PubMed    


    November 2020
  93. LU KH, Broaddus RR
    Endometrial Cancer.
    N Engl J Med. 2020;383:2053-2064.
    PubMed    


    October 2020
  94. CARLSSON LMS, Sjoholm K, Jacobson P, Andersson-Assarsson JC, et al
    Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.
    N Engl J Med. 2020;383:1535-1543.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Obesity is free of charge.